Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18437420 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE | February 2024 | September 2024 | Allow | 8 | 0 | 0 | No | No |
| 18386399 | ETHYL 2-[9-(2-HYDROXYQUINOLIN-3-YL)-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18496821 | 4,5-BIS(4-METHOXYPHENYL)-1-HEXYL-2-(4-NITROPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18493072 | 2-(BENZO[D]OXAZOL-2-YL)-N'-(PICOLINOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18381454 | 9-(2-HYDROXYPHENYL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10- HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18466404 | COSMETIC PRODUCTS INCLUDING BIS-CARBOXY SILICONE POLYMER COMPONENT | September 2023 | April 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18460941 | Ready-To-Use Potassium Phosphates In Sodium Chloride Solutions | September 2023 | December 2023 | Allow | 3 | 0 | 0 | No | No |
| 18360514 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | July 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18329268 | DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING | June 2023 | November 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18322065 | DERMAL SKIN PROTECTANT AND CARRIER | May 2023 | May 2025 | Allow | 24 | 2 | 0 | Yes | No |
| 18315605 | Implantable Device for Sustained Release of a Macromolecular Drug Compound | May 2023 | January 2024 | Allow | 8 | 0 | 0 | No | No |
| 18136916 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE | April 2023 | October 2023 | Allow | 5 | 1 | 0 | No | No |
| 18191874 | AQUEOUS COSMETIC | March 2023 | April 2024 | Allow | 13 | 1 | 1 | No | No |
| 18121679 | NUTRACEUTICAL COMPOSITIONS AND METHODS FOR DIETARY ALLEVIATION OF POLYCYSTIC OVARY SYNDROME | March 2023 | October 2023 | Allow | 7 | 2 | 1 | Yes | No |
| 18179777 | COMPOSITIONS COMPRISING SILK FIBROIN PARTICLES AND USES THEREOF | March 2023 | August 2024 | Allow | 17 | 2 | 0 | No | No |
| 18168958 | PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAME | February 2023 | October 2024 | Abandon | 20 | 1 | 1 | No | No |
| 18097097 | METHOD FOR PRODUCING POWDER LEADS AND PRODUCTS PRODUCED THEREWITH | January 2023 | May 2024 | Allow | 16 | 1 | 1 | No | No |
| 18148860 | INJECTABLE PREPARATION | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 18070186 | ANTIMICROBIAL COMPLEXES | November 2022 | January 2024 | Abandon | 14 | 0 | 1 | No | No |
| 17981080 | SENSITIZING COMPOSITION USING ELECTROMAGNETIC WAVES FOR THERMAL THERAPY OF CANCERS, AND CANCER THERAPY USING SAME | November 2022 | May 2023 | Allow | 7 | 0 | 0 | No | No |
| 17950638 | NOVEL CERIUM OXIDE NANOCOMPLEX AND A COMPOSITION FOR PREVENTING OR TREATING CEREBRAL INFARCTION COMPRISING THE SAME | September 2022 | April 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17945054 | Vitamins and Alpha Keto Acid Compositions for Use in a Treatment Program for Chronic Kidney Disease Patients | September 2022 | August 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17945043 | Vitamins and Alpha Keto Acid Compositions for Use in a Treatment Program for Chronic Kidney Disease Patients | September 2022 | May 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17893991 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | August 2022 | May 2023 | Allow | 9 | 0 | 0 | No | No |
| 17881991 | DOUBLE-STRUCTURED STICK COSMETIC AND MANUFACTURING METHOD THEREOF | August 2022 | January 2024 | Allow | 18 | 1 | 1 | No | No |
| 17876348 | DOSAGE FORM COATING COMPOSITION AND METHOD OF MAKING AND USING THE SAME | July 2022 | May 2025 | Abandon | 34 | 3 | 0 | No | Yes |
| 17842691 | Implantable Pharmaceutical Composition Prepared From Components Consisting of Calcium Sulfate Alpha-Hemihydrate, Vancomycin and Tobramycin | June 2022 | March 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17726312 | Clear Nail Top Coat Compositions And Methods Of Making | April 2022 | May 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17769678 | Clear Nail Top Coat Compositions And Methods Of Making | April 2022 | June 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17711122 | STORAGE STABLE SINCALIDE FORMULATIONS | April 2022 | January 2023 | Allow | 9 | 1 | 0 | No | No |
| 17765196 | PROTOPANAXATRIOL (PPT)-TYPE COMPOUNDS AS ACTIVE INGREDIENTS IN INSECTICIDE PRODUCTS | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17701004 | PHARMACEUTICAL COMPOSITIONS COMPRISING AFATINIB | March 2022 | September 2023 | Allow | 18 | 1 | 0 | No | No |
| 17642589 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | March 2022 | December 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17683840 | METHOD FOR PRODUCING WEARABLE COATING | March 2022 | May 2023 | Allow | 14 | 0 | 0 | No | No |
| 17652559 | SELF-THERAPEUTIC NANOPARTICLE FOR ENHANCED TOPICAL DELIVERY TO SKIN KERATINOCYTES AND TREATING SKIN INFLAMMATION | February 2022 | May 2025 | Allow | 38 | 4 | 1 | No | No |
| 17637841 | SOLID COSMETIC | February 2022 | June 2025 | Allow | 40 | 2 | 0 | No | No |
| 17636732 | METHOD FOR PRODUCING A BIOACTIVE COMPONENT-CONTAINING NANO-COMPOSITE, AND A MONTMORILLONITE-BASED, BIOACTIVE COMPONENT-CONTAINING NANO-COMPOSITE | February 2022 | May 2025 | Allow | 39 | 1 | 1 | No | No |
| 17636661 | NO SCENT NO BITE | February 2022 | April 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17633226 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | February 2022 | March 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17629760 | MEDICATION COATED WITH HEMP OR OTHER CANNABINOID | January 2022 | April 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17627493 | CHEWING GUM COMPOSITIONS FOR THE TREATMENT OF MENSTRUAL PAIN | January 2022 | April 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17646794 | OIL-DISPERSED COMPOSITION AND COSMETICS FOR LIP CARE USING THE SAME | January 2022 | November 2023 | Allow | 23 | 2 | 1 | No | No |
| 17566015 | METHODS OF TREATMENT USING ULTRASMALL NANOPARTICLES TO INDUCE CELL DEATH OF NUTRIENT-DEPRIVED CANCER CELLS VIA FERROPTOSIS | December 2021 | November 2023 | Allow | 22 | 1 | 0 | No | No |
| 17557105 | LONG WEAR LIQUID ANHYDROUS COMPOSITION | December 2021 | March 2024 | Allow | 26 | 1 | 1 | No | No |
| 17553648 | DEODORANT COMPOSITIONS | December 2021 | January 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17550117 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE | December 2021 | January 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 17549495 | ANTICANCER COMPOSITIONS | December 2021 | July 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17618256 | DEODORANT COMPOSITIONS | December 2021 | January 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17526266 | SUGAR-FREE LIP SCRUB COMPOSITIONS AND USES THEREOF | November 2021 | October 2023 | Abandon | 23 | 2 | 0 | Yes | No |
| 17513276 | METHODS OF INCREASING MAGNESIUM BIOAVAILABILITY AND ABSORPTION | October 2021 | September 2023 | Allow | 22 | 1 | 1 | No | No |
| 17507369 | PHARMACEUTICAL FORMULATIONS CONTAINING GABOXADOL FOR THERAPEUTIC TREATMENT | October 2021 | May 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17502181 | DRUG DELIVERY CARRIER INCLUDING PLGA AND BETA-CYCLODEXTRIN CONTAINING DRUG | October 2021 | January 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17499001 | Ready-To-Use Potassium Phosphates In Sodium Chloride Solutions | October 2021 | September 2023 | Allow | 23 | 0 | 0 | No | No |
| 17490797 | METHOD FOR TREATING MYOPIA AND APPLICATION IN PREPARATION OF MEDICAMENT | September 2021 | May 2024 | Abandon | 31 | 2 | 1 | Yes | No |
| 17484725 | DRUG DELIVERY SYSTEM FOR TREATMENT OF CANCER | September 2021 | June 2025 | Allow | 44 | 2 | 0 | No | No |
| 17480892 | HAIR CONDITIONING COMPOSITION | September 2021 | April 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17439829 | COMPOSITIONS COMPRISING CURCUMIN AND COENZYME Q10 | September 2021 | August 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17475741 | LAVAGE TECHNIQUES AND VIRUCIDAL COMPOSITIONS COMPRISING HYPOCHLOROUS SOLUTIONS | September 2021 | March 2025 | Abandon | 42 | 3 | 0 | No | No |
| 17473826 | Dental Local Anesthetic Solution | September 2021 | February 2023 | Abandon | 17 | 2 | 1 | No | No |
| 17468401 | ANTIPERSPIRANT AND DEODORANT FORMULATION AND METHOD OF PROCESSING THE SAME | September 2021 | June 2023 | Abandon | 21 | 1 | 1 | No | No |
| 17462404 | EYELASH COATING COMPOSITIONS FOR FALSE EYELASHES | August 2021 | January 2024 | Abandon | 29 | 2 | 1 | No | No |
| 17397444 | STORAGE STABLE SINCALIDE FORMULATIONS | August 2021 | January 2022 | Allow | 5 | 0 | 0 | Yes | No |
| 17444469 | INJECTABLE PREPARATION | August 2021 | October 2022 | Allow | 14 | 0 | 0 | Yes | No |
| 17387420 | COSMETIC COMPOSITION | July 2021 | August 2024 | Abandon | 37 | 2 | 1 | No | No |
| 17376733 | PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAME | July 2021 | February 2023 | Abandon | 19 | 1 | 0 | No | No |
| 17366863 | NON-DIGESTIBLE CAPSULES FOR THE DELIVERY OF FLUID ABSORBING MATERIALS | July 2021 | March 2025 | Abandon | 45 | 4 | 0 | Yes | Yes |
| 17345462 | STARCH-BASED RELEASE MODIFYING EXCIPIENTS AND PHARMACEUTICAL COMPOSITIONS DERIVED THEREFROM | June 2021 | August 2022 | Allow | 14 | 0 | 0 | No | No |
| 17303915 | DERMAL SKIN PROTECTANT AND CARRIER | June 2021 | February 2023 | Allow | 20 | 1 | 0 | No | No |
| 17342368 | SHEAR-THINNING SELF-HEALING NETWORKS | June 2021 | August 2022 | Allow | 14 | 1 | 0 | No | No |
| 17334670 | Formulation for and Method of Using an Herbal Tea for the Treatment of Urinary Tract Infections | May 2021 | October 2023 | Abandon | 28 | 0 | 1 | No | No |
| 17326327 | OILY STICK-SHAPED COSMETIC | May 2021 | November 2022 | Allow | 18 | 1 | 0 | No | No |
| 17319496 | TETRAHYDROCURCUMINOID-METAL COMPLEXES, MANUFACTURING METHODS THEREOF, AND USES THEREOF | May 2021 | August 2024 | Abandon | 39 | 2 | 1 | No | No |
| 17316208 | DRUG-DEVICE UNIT CONTAINING QUINAGOLIDE | May 2021 | February 2024 | Abandon | 34 | 2 | 1 | No | No |
| 17292238 | Pharmaceutical Composition For Preventing Or Treating Obesity, Containing CYCLO(HIS-PRO) As Active Ingredient | May 2021 | December 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17290360 | MOSQUITO ATTRACTANT FORMULATIONS AND USES THEREOF | April 2021 | April 2025 | Allow | 48 | 2 | 1 | Yes | No |
| 17285234 | THERAPEUTIC OR PROPHYLACTIC AGENT FOR NOCTURNAL POLYURIA | April 2021 | November 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17282999 | GEL, IN PARTICULAR FOR USE IN A WOUND TREATMENT AGENT | April 2021 | November 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17219479 | SENSITIZING COMPOSITION USING ELECTROMAGNETIC WAVES FOR THERMAL THERAPY OF CANCERS, AND CANCER THERAPY USING SAME | March 2021 | February 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17279972 | OIL-IN-WATER TYPE SUNSCREEN COSMETIC | March 2021 | December 2023 | Allow | 32 | 0 | 1 | No | No |
| 17212397 | Volume Boosting Molding Hair Coloring Creme Formulation | March 2021 | January 2023 | Abandon | 22 | 1 | 0 | No | No |
| 17278756 | PERACETIC ACID STABILIZED COMPOSITIONS WITH STABLE LINING | March 2021 | March 2024 | Allow | 36 | 0 | 0 | No | No |
| 17200766 | COMPOSITIONS COMPRISING SILK FIBROIN PARTICLES AND USES THEREOF | March 2021 | November 2022 | Allow | 21 | 3 | 1 | No | No |
| 17200764 | COMPOSITIONS COMPRISING SILK FIBROIN PARTICLES AND USES THEREOF | March 2021 | November 2022 | Allow | 21 | 3 | 1 | No | No |
| 17271869 | MATERIALS CONTAINING COPPER AND THEIR USE IN BENEFICIAL BODY HEALTH | February 2021 | May 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17271790 | COMPOSITION FOR IMPROVING SKIN TRANSPARENCY AND REDUCING DULLNESS | February 2021 | September 2023 | Allow | 30 | 0 | 0 | Yes | No |
| 17271146 | IMPROVED CANNABINOID BIOAVAILABILITY | February 2021 | March 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17271152 | ORAL FORMULATIONS OF LAVENDER AND CANNABINOIDS | February 2021 | March 2024 | Abandon | 36 | 0 | 1 | No | No |
| 17269590 | LUBRICATION METHOD | February 2021 | October 2023 | Allow | 32 | 0 | 0 | No | No |
| 17269311 | Supplement for animal feed for sucking pigs | February 2021 | September 2024 | Abandon | 43 | 2 | 0 | No | No |
| 17267325 | COSMETIC PRODUCT | February 2021 | August 2024 | Allow | 42 | 1 | 1 | No | No |
| 17264683 | WATER-CONTAINING LIPSTICK AND PREPARATION METHOD THEREFOR | January 2021 | December 2022 | Abandon | 23 | 2 | 1 | No | No |
| 17159960 | LIP COMPOSITION | January 2021 | October 2024 | Allow | 45 | 4 | 0 | No | No |
| 17261929 | DERMATOLOGICAL COMPOSITIONS FOR PROVIDING NUTRIENTS TO SKIN AND METHODS THEREOF | January 2021 | May 2025 | Abandon | 51 | 5 | 1 | No | Yes |
| 17139370 | THERAPEUTIC AGENT FOR HYPERPHOSPHATEMIA AND PARTICLES | December 2020 | September 2024 | Abandon | 45 | 4 | 0 | Yes | No |
| 17124668 | Ready to Use Injectable formulations of Melphalan and processes for preparation thereof | December 2020 | August 2023 | Allow | 32 | 3 | 1 | Yes | No |
| 17120547 | Solid honey product and method of producing the same | December 2020 | December 2023 | Abandon | 36 | 2 | 0 | No | No |
| 17117967 | PHARMACEUTICAL COMPOSITION COMPRISING AMNIOTIC FLUID STEM CELL SPHEROID AND THE USE THEREOF IN TREATMENT OF URINARY INCONTINENCE | December 2020 | February 2023 | Allow | 26 | 2 | 1 | No | No |
| 17110982 | Glue-free Adhesive Eyeleashes | December 2020 | April 2022 | Abandon | 16 | 1 | 0 | No | No |
| 16956047 | COSMETIC COMPOSITION COMPRISING A CAESALPINIA SPINOSA EXTRACT, A KAPPAPHYCUS ALVAREZII EXTRACT, AT LEAST ONE PREBIOTIC AND A PROBIOTIC | December 2020 | March 2025 | Abandon | 57 | 4 | 1 | No | No |
| 17108939 | INJECTABLE PREPARATION | December 2020 | June 2021 | Allow | 7 | 1 | 0 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AL-AWADI, DANAH J.
With a 28.6% reversal rate, the PTAB affirms the examiner's rejections in the vast majority of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 20.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner AL-AWADI, DANAH J works in Art Unit 1615 and has examined 822 patent applications in our dataset. With an allowance rate of 53.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 33 months.
Examiner AL-AWADI, DANAH J's allowance rate of 53.3% places them in the 9% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by AL-AWADI, DANAH J receive 2.56 office actions before reaching final disposition. This places the examiner in the 87% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by AL-AWADI, DANAH J is 33 months. This places the examiner in the 26% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +15.6% benefit to allowance rate for applications examined by AL-AWADI, DANAH J. This interview benefit is in the 59% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 18.8% of applications are subsequently allowed. This success rate is in the 11% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.6% of cases where such amendments are filed. This entry rate is in the 18% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 84.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 63% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 61.1% of appeals filed. This is in the 33% percentile among all examiners. Of these withdrawals, 57.6% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 57.3% are granted (fully or in part). This grant rate is in the 73% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 2.7% of allowed cases (in the 81% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 49% percentile). This examiner issues Quayle actions less often than average. Allowances may come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.